QTTB
Q32 Bio Inc.2.8800
-0.1700-5.57%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
35.44MP/E (TTM)
-Basic EPS (TTM)
-3.40Dividend Yield
0%Recent Filings
8-K
SIGNAL-AA enrollment done
Q32 Bio completed enrollment in SIGNAL-AA Phase 2a Part B for bempikibart in alopecia areata, expanding to 33 patients with 36-week topline data due mid-2026. Sold ADX-097 to Akebia for $12M guaranteed payments plus milestones up to $592M; raised $10.5M via RDO. Cash hit $48.3M at year-end, funding into Q4'27. Clinical risks loom.
10-K
FY2025 results
Q32 Bio posted FY2025 net income of $29.8M, driven by $53.7M non-cash collaboration revenue from settling prior obligations with Amgen via equity issuance, erasing a $55M refund liability. R&D expenses fell 40% to $19.2M as the company restructured in February, halted ADX-097's Phase 2 trial, and sold ADX-097 assets to Akebia for $7M upfront (plus $3M in six months and $2M near-term milestone), netting $11.7M gain. Cash burned $33.5M operationally but ended at $48.3M, sufficient into Q4 2027 with recent financing and milestones. Bempikibart's SIGNAL-AA Part B enrolled 33 severe AA patients; 36-week data due mid-2026. Clinical failure could derail funding.
8-K
Q32 Bio raises $10.5M
Q32 Bio inked a $10.5M registered direct offering on February 17, 2026, selling 1,666,679 common shares at $3.90 and pre-funded warrants for 1,025,654 shares, closing February 18. Funds will fuel working capital, research, and bempikibart's alopecia areata trials. Cash extends runway. Closing hinges on conditions.
8-K
Iwicki withdraws resignation
Q32 Bio's Board Chair Mark Iwicki withdrew his resignation on December 17, 2025, effective immediately, reversing his planned December 31 exit to focus on Inhibikase Therapeutics. The Board fully backed his decision to stay on amid his reduced board commitments. Continuity preserved. This stabilizes governance at a pivotal time.
8-K
Sells ADX-097, extends runway
Q32 Bio sold its ADX-097 complement inhibitor assets to Akebia on November 28, 2025, for $7.0 million upfront, $3.0 million in six months, and a $2.0 million near-term milestone. This non-dilutive cash bolsters the runway into H2 2027, funding bempikibart trials through mid-2026 data. Cash extends further than before.
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
FBRX
Forte Biosciences, Inc.
23.27+1.31
HCWB
HCW Biologics Inc.
1.78-0.09
IMA
ImageneBio, Inc.
6.25+0.08
INMB
INmune Bio Inc.
1.89-0.02
KALA
KALA BIO, Inc.
0.56-0.05
XBIT
XBiotech Inc.
2.45-0.08
XLO
Xilio Therapeutics, Inc.
0.65+0.00
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZURA
Zura Bio Limited
4.12+0.05